Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo Controlled, Double-blind, Double-dummy Three-way Cross Over Trial to Investigate the Effect of BI 409306, BI 425809 and Lamotrigine on Ketamine-induced Cognitive Deficits in Healthy Male Subjects

NCT04602221 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04602221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04602221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo Controlled, Double-blind, Double-dummy Three-way Cross Over Trial to Investigate the Effect of BI 409306, BI 425809 and Lamotrigine on Ketamine-induced Cognitive Deficits in Healthy Male Subjects
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
December 1, 2020
Completion date
August 12, 2022
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy